Risk evaluation of coronary heart disease and cerebrovascular disease by the Japan Atherosclerosis Society Guidelines 2002 using the cohort of the Holicos-PAT study.

Our purpose in this study was to evaluate the new JAS guidelines as a risk assessment tool in Japanese patients with hypercholesterolemia, using the cohort of the Holicos-PAT study. The Holicos-PAT study was designed as a prospective observational study. 2039 patients were followed with or without pravastatin for 5 years. We assessed coronary heart disease (CHD) and cerebrovascular disease (CVD) risks by the patient categories described in the JAS guidelines. In the Holicos-PAT study, the primary endpoints were CHD, and the secondary endpoints were CVD and total mortality. CHD event includes onset and worsening of angina pectoris, performing CABG or PTCA, non-fatal and fatal myocardial infarction, and death from CHD including heart death and sudden death. CVD events are onset or recurrence of cerebral infarction, onset of cerebral hemorrhage, and death from cerebral infarction or hemorrhage. The event rates were calculated by the person-years method, and the differences in event rates between category groups were analyzed by chi-square test. The event rates of CHD in Category A, B1, B2, B3, B4 and C, were 1.1, 4.0, 2.8, 5.7, 18.2 and 38.8 per 1,000 person-years. The rates of CHD events in the higher risk category groups, Category B4 group (p = 0.004 in whole patients) and C group (p < 0.001 in whole patients), were significantly higher than that in the combined category groups A + B1 + B2. The event rates of CVD in Category A, B1, B2, B3, B4 and C, were 2.1, 1.8, 1.8, 0.6, 10.8 and 6.4 per 1,000 person-years. The event rates of CHD in men were significantly higher than those in women, in categories B4 (p < 0.001) and C (p < 0.001). From these results, each category classified by accumulation of risk factors, showed increasing event rates of CHD and CVD. The categories in the JAS guidelines are useful to assess CHD and CVD risk in Japanese patients with hypercholesterolemia. However, the risk evaluation by the JAS guideline categories may underestimate the risk in men and overestimate it in women.

[1]  Michael Pignone,et al.  Framingham-based tools to calculate the global risk of coronary heart disease , 2003, Journal of general internal medicine.

[2]  U. Broedl,et al.  Comparison of current guidelines for primary prevention of coronary heart disease , 2003, Journal of General Internal Medicine.

[3]  Y. Matsuzawa,et al.  Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[4]  Y. Matsuzawa,et al.  Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[5]  G. Assmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.

[6]  D. Kent,et al.  The Framingham scores overestimated the risk for coronary heart disease in Japanese, Hispanic, and native American cohorts , 2002, ACP journal club.

[7]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[8]  J. Sasaki,et al.  Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study (KLIS) , 2000 .

[9]  D. Bhatnagar,et al.  Indications for cholesterol-lowering medication: comparison of risk-assessment methods , 1999, The Lancet.

[10]  K. Pyörälä,et al.  Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. , 1998, European heart journal.

[11]  Petros Nihoyannopoulos,et al.  Joint British recommendations on prevention of coronary heart disease in clinical practice , 1998, Heart.

[12]  L. Ramsay,et al.  Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table , 1996, The Lancet.

[13]  M. Fujishima,et al.  Diabetes and Cardiovascular Disease in a Prospective Population Survey in Japan: The Hisayama Study , 1996, Diabetes.

[14]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.

[15]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[16]  T. Hashimoto,et al.  Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980–1994 , 2004, European Journal of Epidemiology.

[17]  H. Mabuchi,et al.  Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT). , 2002, Journal of atherosclerosis and thrombosis.

[18]  Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. , 2000, Journal of atherosclerosis and thrombosis.